Cubist Systematic Strategies LLC Has $54,000 Stake in Generation Bio Co. (NASDAQ:GBIO)

Cubist Systematic Strategies LLC increased its holdings in shares of Generation Bio Co. (NASDAQ:GBIO) by 91.0% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 19,046 shares of the company’s stock after purchasing an additional 9,075 shares during the quarter. Cubist Systematic Strategies LLC’s holdings in Generation Bio were worth $54,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in the business. The Manufacturers Life Insurance Company boosted its holdings in Generation Bio by 8.7% during the second quarter. The Manufacturers Life Insurance Company now owns 164,573 shares of the company’s stock worth $464,000 after purchasing an additional 13,104 shares during the last quarter. American Century Companies Inc. boosted its holdings in Generation Bio by 199.3% during the second quarter. American Century Companies Inc. now owns 31,786 shares of the company’s stock worth $90,000 after purchasing an additional 21,167 shares during the last quarter. Acadian Asset Management LLC boosted its holdings in Generation Bio by 23.9% during the second quarter. Acadian Asset Management LLC now owns 594,569 shares of the company’s stock worth $1,675,000 after purchasing an additional 114,734 shares during the last quarter. Rhumbline Advisers boosted its holdings in Generation Bio by 7.4% during the second quarter. Rhumbline Advisers now owns 78,903 shares of the company’s stock worth $222,000 after purchasing an additional 5,430 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its position in shares of Generation Bio by 31.2% in the second quarter. Bank of New York Mellon Corp now owns 186,756 shares of the company’s stock valued at $527,000 after purchasing an additional 44,378 shares during the period. Institutional investors and hedge funds own 95.22% of the company’s stock.

Generation Bio Stock Up 1.7 %

Shares of Generation Bio stock opened at $2.46 on Thursday. The company has a market capitalization of $163.66 million, a price-to-earnings ratio of -0.96 and a beta of 2.80. Generation Bio Co. has a 12-month low of $0.86 and a 12-month high of $4.65. The firm’s 50-day moving average price is $2.50 and its two-hundred day moving average price is $2.89.

Generation Bio (NASDAQ:GBIO) last announced its quarterly earnings data on Wednesday, August 7th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.04). Generation Bio had a negative return on equity of 92.86% and a negative net margin of 1,202.56%. The firm had revenue of $4.09 million for the quarter, compared to analyst estimates of $3.23 million. On average, sell-side analysts expect that Generation Bio Co. will post -1.8 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the stock. Needham & Company LLC reissued a “buy” rating and issued a $10.00 price objective on shares of Generation Bio in a research report on Thursday, August 8th. Wedbush reissued an “outperform” rating and issued a $5.00 price objective on shares of Generation Bio in a research report on Thursday, August 8th. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $7.50.

About Generation Bio

Generation Bio Co develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems.